Funded Tech Companies
Amani Therapeutics
Operating out of New York, Amani Therapeutics has funding from private investors.
Company Overview
Company Name
Amani Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
40 10th Avenue, 7th Floor
New York, NY 10014
USA
New York, NY 10014
USA
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Driving innovative science to deliver safer and more effective psychiatric treatments to patients -- faster. Amani's lead program, AM-01, is a fixed-dose combination product that includes clozapine and a Phase 3--ready NCE with worldwide rights in-licensed from AstraZeneca. Amani believes AM-01 has the potential to deliver clozapine's unmatched efficacy for patients with schizophrenia while addressing clozapine's most significant safety liability--severe neutropenia--and the burdensome blood-monitoring that limit its use. Clozapine remains the only medication proven to meaningfully improve symptoms in treatment-resistant schizophrenia and to reduce suicide risk in patients with schizophrenia and schizoaffective disorder. Despite its clinical benefits, it is profoundly underutilized due to safety concerns and monitoring requirements.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
3/24/2026
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Medical Officer
Carla Canuso
Chief Operating Officer
Rob Swoboda
Vice President
Praveen Kandi
VP - Operations
Tricia Cotter
Company Investors
Browse more funded tech companies:
Share this article
About Our VC Funding Database
This tech company profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs